ASPIRA PATHLAB & DIAGNOSTICS LIMITED Financials Aspira Pathlab & Diagnostics Limited
Equities
ASPIRA
INE500C01017
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.52 INR | -1.45% |
|
+7.81% | -22.10% |
| 04-03 | Aspira Pathlab Forms New Limited Liability Partnership | MT |
| 04-01 | Aspira Pathlab Opens Two Diagnostic Centers in India | MT |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 38.2 | 142 | 355.9 | 293.4 | 667 | 286.7 |
| Enterprise Value (EV) 1 | 144.8 | 211.7 | 443.7 | 302.3 | 689.8 | 296.3 |
| P/E ratio | -1.58 x | -3.69 x | -7.74 x | 19.7 x | 15 x | -309 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.88 x | 1.86 x | 4.23 x | 1.93 x | 3.41 x | 1.98 x |
| EV / Revenue | 3.32 x | 2.77 x | 5.27 x | 1.99 x | 3.53 x | 2.05 x |
| EV / EBITDA | -3.69 x | -6.41 x | -19.4 x | 10.1 x | 12.1 x | 35.9 x |
| EV / FCF | -3.2 x | -8.06 x | -16.6 x | 13.8 x | 72.5 x | 9.88 x |
| FCF Yield | -31.3% | -12.4% | -6.01% | 7.24% | 1.38% | 10.1% |
| Price to Book | 26.3 x | 85.6 x | -31.5 x | 8.67 x | 8.49 x | 3.67 x |
| Nbr of stocks (in thousands) | 2,250 | 5,193 | 9,293 | 10,293 | 10,293 | 10,293 |
| Reference price 2 | 16.98 | 27.35 | 38.30 | 28.50 | 64.80 | 27.85 |
| Announcement Date | 18-08-11 | 19-08-30 | 21-08-30 | 21-08-30 | 22-08-18 | 23-08-31 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 43.58 | 76.37 | 84.16 | 152.1 | 195.4 | 144.7 |
| EBITDA 1 | -39.27 | -33.02 | -22.86 | 30.04 | 56.79 | 8.263 |
| EBIT 1 | -49.98 | -44.75 | -34.88 | 20.69 | 47.38 | 0.257 |
| Operating Margin | -114.69% | -58.6% | -41.44% | 13.61% | 24.24% | 0.18% |
| Earnings before Tax (EBT) 1 | -55.82 | -51.83 | -42.12 | 13.81 | 44.59 | -0.887 |
| Net income 1 | -55.82 | -51.83 | -42.41 | 13.81 | 44.59 | -0.887 |
| Net margin | -128.1% | -67.86% | -50.38% | 9.08% | 22.82% | -0.61% |
| EPS 2 | -10.75 | -7.412 | -4.950 | 1.450 | 4.330 | -0.0900 |
| Free Cash Flow 1 | -45.31 | -26.25 | -26.66 | 21.89 | 9.514 | 29.98 |
| FCF margin | -103.97% | -34.37% | -31.68% | 14.4% | 4.87% | 20.71% |
| FCF Conversion (EBITDA) | - | - | - | 72.9% | 16.75% | 362.84% |
| FCF Conversion (Net income) | - | - | - | 158.54% | 21.33% | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 18-08-11 | 19-08-30 | 21-08-30 | 21-08-30 | 22-08-18 | 23-08-31 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 107 | 69.6 | 87.8 | 8.97 | 22.8 | 9.64 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -2.714 x | -2.109 x | -3.841 x | 0.2985 x | 0.4011 x | 1.167 x |
| Free Cash Flow 1 | -45.3 | -26.3 | -26.7 | 21.9 | 9.51 | 30 |
| ROE (net income / shareholders' equity) | -179% | -188% | -94.3% | 22.8% | 42.3% | -0.69% |
| ROA (Net income/ Total Assets) | -22.8% | -20.5% | -15% | 9.9% | 19.8% | 0.09% |
| Assets 1 | 244.7 | 253.2 | 283.4 | 139.4 | 225.2 | -980.1 |
| Book Value Per Share 2 | 0.6400 | 0.3200 | -1.220 | 3.290 | 7.640 | 7.600 |
| Cash Flow per Share 2 | 0.4300 | 0.1200 | 0.1000 | 1.150 | 1.320 | 0.5500 |
| Capex 1 | 9.83 | 5.1 | 0.44 | 1.24 | 5.99 | 1.31 |
| Capex / Sales | 22.56% | 6.68% | 0.52% | 0.81% | 3.06% | 0.91% |
| Announcement Date | 18-08-11 | 19-08-30 | 21-08-30 | 21-08-30 | 22-08-18 | 23-08-31 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -22.10% | 3.83M | |
| -22.04% | 8.54B | |
| +67.47% | 4.32B | |
| -0.82% | 2.53B | |
| -39.22% | 2.48B | |
| -8.65% | 1.9B | |
| -17.46% | 1.59B | |
| -40.70% | 1.23B | |
| +13.38% | 1.13B | |
| +16.15% | 994M |
- Stock Market
- Equities
- ASPIRA Stock
- Financials Aspira Pathlab & Diagnostics Limited
